medigraphic.com
ISSN 0210-5187 (Electronic)

2016, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2016; 44 (1)

PASI reduction in patients with moderate-severe psoriasis treated with biological therapy. Experience in a Peruvian Tertiary Hospital

Bravo EA, Bar N, Paucar S, Mendoza R

Language: Spanish
References: 19
Page: 41-44
PDF size: 284.16 Kb.


ABSTRACT

Objective: To determine the level of reduction in PASI (Psoriasis Severity Index) in patients with moderate- severe psoriasis treated with biological therapy. Material and methods: 36 patients during the period January 2009-December 2013 met the criteria for Moderate-Severe Psoriasis (percentage of body surface and/or PASI › 10) who were treated with biological agents. PASI at week 0 and week 12 of treatment, and the PASI50 and PASI 75 was determined. Biological agents used were infliximab, etanercept, adalumumab and ustekinumab. Tables and graphs were processed using SPSS 19. Results: The therapeutic benefit was obtained in 94.44% of patients. The overall reduction in PASI at 12 weeks was 67.56%. 77.78 and 52.7% of patients achieved PASI 75 and PASI50 respectively. Conclusions: The efficacy of biological agents was evidenced by a sharp decrease in PASI at 12 weeks of treatment. The tendency of improvement by the type of biological agent was similar to that described in the literature.


REFERENCES

  1. Moreno-Ramírez E, Fonseca P, Herranz M. Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión. Actas Dermosifiliogr. 2010; 101: 858-865.

  2. Wahl AK, Robinson HS, Langeland E, Larsen MH, Krogstad AL, Moum T. Clinical characteristics associated with illness perception in psoriasis. Acta Derm Venereol. 2014; 94 (3): 271-275.

  3. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23 (Suppl 2): 1-70.

  4. Puig L, Carrascosa JM, Daudén E et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009; 100 (5): 386-413.

  5. Wozel G. Guías para el tratamiento de la psoriasis. Retos y opciones: ¿Hacia dónde nos dirigimos? Med Cutan Iber Lat Am. 2005; 33 (1): 41-42.

  6. Blasco A, Lázaro P, Ferrándiz C, García-Díez A, Lisod J. Eficiencia de los agentes biológicos en el tratamiento de la psoriasis moderada-grave. Actas Dermo-Sifiliográficas. 2009; 100 (9): 792-803.

  7. Puig L, Fan T, Ding Q, Smith NE. Predictors of biologic treatment of psoriasis: a non-interventional study. Clinicoecon Outcomes Res. 2014; 6: 93-100.

  8. Tsai TF, Yeh TY. The use of biologics for psoriasis in Asia-Pacific region. Curr Rheumatol Rev. 2009; 5: 149-152.

  9. Chiu HY, Wang TS, Cho YT, Tsai TF. Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol. 2013; 52 (6): 673-680.

  10. Noda S, Mizuno K, Adachi M. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital. J Dermatol. 2012; 39 (3): 265-268.

  11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet. 2001; 357: 1842-1847.

  12. Valdés DP, Schroeder F, Roizen V, Honeyman J, Sánchez L. Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar de moderada a severa en tratamiento con infliximab. Rev Méd Chile. 2006; 134 (3): 326-331.

  13. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab versus methotrexate versus placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008; 158 (3): 558-566.

  14. Meng Y, Dongmei L, Yanbin P, Jinju F, Meile T, Binzhu L et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014; 39 (6): 696-707.

  15. González-Guerra E. Ustekinumab dentro de las terapéuticas hospitalarias. Med Cutan Iber Lat Am. 2012; 40 (2): 49-57.

  16. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011; 63 (3): 154-163.

  17. Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013; 88 (5): 760-763.

  18. López AA, Rosas LS. Biological agents in psoriasis. A report of our practical experience. Dermatología Cosmética Médica y Quirúrgica. 2014; 12 (2): 124-128.

  19. Warren RB, Brown BC, Lavery D, Ashcroft DM, Griffiths CE. Biologic therapies for psoriasis: practical experience in a UK tertiary referral centre. Br J Dermatol. 2009; 160 (1): 162-169.




2020     |     www.medigraphic.com